Vertex Pharmaceuticals Current Valuation

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

 Earnings Call  This Week

Vertex Pharmaceuticals current-valuation fundamental analysis lookup allows you to check this and other indicators for Vertex Pharmaceuticals Incorpor or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools
Symbol
Refresh

Vertex Pharmaceuticals Current Valuation Analysis

Enterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
 2017 2018 2019 2020 (projected)
Receivables310.25 M414.87 M373.38 M402.86 M
Inventories111.83 M124.36 M111.92 M120.76 M
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKOSYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase III clinical trial VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain CTX001 that is in Phase III clinical trial for the treatment of beta-thalassemia and sickle cell diseases and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG Arbor Biotechnologies, Inc. Moderna Therapeutics, Inc. Genomics plc Merck KGaA Darmstadt, Germany X-Chem, Inc. Janssen Pharmaceuticals, Inc. Merck KGaA Kymera Therapeutics Ribometrix, Inc. and Molecular Templates, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
ReceivablesInventories
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
More About Current Valuation | All Equity Analysis
Vertex Pharmaceuticals Current Valuation  =
53.1 B
ValuationFundamentalsBuy or Sell

Vertex Pharmaceuticals Current Valuation Over Time Pattern

 Vertex Pharmaceuticals Enterprise Value 
    
  Timeline 

About Current Valuation

Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Compare to competition
Accumulated Other Comprehensive Income
In accordance with recently published financial statements Vertex Pharmaceuticals Incorpor has Current Valuation of 53.1 B. This is 269.69% higher than that of the Healthcare sector, and 1043.06% higher than that of Biotechnology industry, The Current Valuation for all stocks is 219.41% lower than the firm.

Did you try this?

Run Instant Ratings Now

   

Instant Ratings

Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Vertex Pharmaceuticals current financial ratios